天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Ifosfamid

Ifosfamide Struktur
3778-73-2
CAS-Nr.
3778-73-2
Bezeichnung:
Ifosfamid
Englisch Name:
Ifosfamide
Synonyma:
IF;ISOPHOSPHAMIDE;Ifosfamide sterile;3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2h-1,3,2-oxazaphosphorine 2-oxide;Ifex;mitoxana;z4942;cyfos;A-4942;mjf9325
CBNumber:
CB7489350
Summenformel:
C7H15Cl2N2O2P
Molgewicht:
261.09
MOL-Datei:
3778-73-2.mol

Ifosfamid Eigenschaften

Schmelzpunkt:
48°C
Siedepunkt:
336.1±52.0 °C(Predicted)
Dichte
1.33±0.1 g/cm3(Predicted)
storage temp. 
Inert atmosphere,2-8°C
L?slichkeit
DMF:50.0(Max Conc. mg/mL);191.51(Max Conc. mM)
DMSO:44.0(Max Conc. mg/mL);168.53(Max Conc. mM)
Ethanol:51.0(Max Conc. mg/mL);195.34(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);38.3(Max Conc. mM)
Water:52.0(Max Conc. mg/mL);199.17(Max Conc. mM)
pka
1.44±0.20(Predicted)
Aggregatzustand
Solid
Farbe
White to off-white
CAS Datenbank
3778-73-2(CAS DataBase Reference)
IARC
3 (Vol. 26, Sup 7) 1987
EPA chemische Informationen
Isophosphamide (3778-73-2)
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
Kennzeichnung gef?hrlicher T
R-S?tze: 25-36
S-S?tze: 26-45
RIDADR  3249
WGK Germany  3
RTECS-Nr. RP6050000
HazardClass  6.1(b)
PackingGroup  III
HS Code  29349990
Giftige Stoffe Daten 3778-73-2(Hazardous Substances Data)
Toxizit?t LD50 in rats (mg/kg): 160 i.p. (Arnold, 1973); also reported as 150 i.p. (Brock)
Bildanzeige (GHS) GHS hazard pictogramsGHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H301 Giftig bei Verschlucken. Akute Toxizit?t oral Kategorie 3 Achtung GHS hazard pictogramssrc="/GHS06.jpg" width="20" height="20" /> P264, P270, P301+P310, P321, P330,P405, P501
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
H340 Kann genetische Defekte verursachen. Keimzellmutagenit?t Kategorie 1B Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" />
H350 Kann Krebs verursachen. Karzinogenit?t Kategorie 1A Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" />
H360 Kann die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. Fertility (Fruchtbarkeit) Kategorie 1 Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" />
Sicherheit
P201 Vor Gebrauch besondere Anweisungen einholen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.

Ifosfamid Chemische Eigenschaften,Einsatz,Produktion Methoden

R-S?tze Betriebsanweisung:

R25:Giftig beim Verschlucken.
R36:Reizt die Augen.

S-S?tze Betriebsanweisung:

S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn m?glich, dieses Etikett vorzeigen).

Chemische Eigenschaften

Crystalline Solid

Verwenden

A cytostatic agent, related structurally to cyclophosphamide

Definition

ChEBI: The simplest member of the class of ifosfamides that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by 2-chloroethyl groups on both the nitrogen atoms respectively. It is a nitrogen mustard alkylating agent used in the treatment of advanced breast c ncer.

Indications

Ifosfamide (Ifex) is an analogue of cyclophosphamide that requires metabolic activation to form 4-hydroxyifosfamide. In general, the metabolism, serum half-life, and excretion of ifosfamide are similar to those of cyclophosphamide.
Ifosfamide is active against a broad spectrum of tumors, including germ cell cancers of the testis, lymphomas, sarcomas, and carcinomas of the lung, breast, and ovary. It is thought to be more active than cyclophosphamide in germ cell cancers and sarcomas.
Ifosfamide is less myelosuppressive than cyclophosphamide but is more toxic to the bladder. It also may produce alopecia, nausea, vomiting, infertility, and second tumors, particularly acute leukemias. Neurological symptoms including confusion, somnolence, and hallucinations have also been reported. It is recommended that ifosfamide be coadministered with the thiol compound mesna (Mesnex) to avoid hemorrhagic cystitis.

Allgemeine Beschreibung

Ifosfamide is available in 1- and 3-g vials for IV administrationas Food and Drug Administration (FDA)-approvedthird-line therapy in the treatment of testicular cancer. It has also been utilized (although not FDA approved) in the treatmentof a wide variety of cancers including Hodgkin’s andnon-Hodgkin’s lymphoma, soft tissue sarcoma, germ celltumors, small cell lung cancer, non–small cell lung cancer(NSCLC), cancers of the head and neck, bladder cancer, cervicalcancer, and Ewing sarcoma. Coadministration ofmesna is recommended. The mechanisms of resistance areidentical to those seen with cyclophosphamide. The drug iswidely distributed with a low extent of protein binding(20%). Metabolism primarily by CYP3A4/5 and CYP2B6 isrequired for activation of the compound. Theagent is administered as the racemic mixture as a result ofthe presence of the chiral phosphorus atom, and differentialmetabolism of the R- and S-isomers has been observed. Incontrast to cyclophosphamide, there is a greater amount ofdeactivation of the agent by N-dechloroethylation and subsequentlymore chloroacetaldehyde is produced, which mayresult in a greater amount of neurotoxicity and nephrotoxicitythan seen with cyclophosphamide. The N-dechloroethylatedmetabolites are the predominate species seen in theplasma. The parent and metabolites are eliminated inthe urine with an elimination half-life of 3 to 10 hours. Themajor components found in the urine are the dechlorethylatedmetabolites. Dose-limiting toxicities include myelosuppressionand bladder toxicity. Other adverse effectsinclude nausea, alopecia, amenorrhea, inappropriate secretionof antidiuretic hormone, as well as the production ofsecondary cancers. Neurotoxicity, which is associated withthe production of chloroacetaldehyde presents as confusion,seizure, weakness, and hallucination, and coma may occur.

Clinical Use

Ifosamide currently is used as “third-line” therapy against testicular cancer, although it also has shown activity in a number of solid tumors and hematologic cancers.

Nebenwirkungen

Patients on ifosfamide (but not cyclophosphamide) commonly exhibit central nervous system (CNS) toxicity. In severe forms, CNS depression can progress to coma and death.

Ifosfamid Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Ifosfamid Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 489)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Hebei Chuanghai Biotechnology Co,.LTD
+86-13131129325
sales1@chuanghaibio.com China 5889 58
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886
info@dakenam.com China 18751 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21634 55
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29880 58
SHANDONG ZHI SHANG CHEMICAL CO.LTD
+86 18953170293
sales@sdzschem.com China 2930 58
Jinan Shengqi pharmaceutical Co,Ltd
86+18663751872
christine@shengqipharm.com CHINA 491 58
Xiamen AmoyChem Co., Ltd
+86-86-5926051114 +8618959220845
sales@amoychem.com China 6383 58
Hubei xin bonus chemical co. LTD
86-13657291602
linda@hubeijusheng.com CHINA 22963 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Beijing Yibai Biotechnology Co., Ltd
0086-182-6772-3597
sales04@yibaibiotech.com CHINA 419 58

3778-73-2(Ifosfamid)Verwandte Suche:


  • holoxan
  • holoxan1000
  • iphosphamide
  • isoendoxan
  • isofosfamide
  • mjf9325
  • n-(2-chloraethyl)-n’-(2-chloraethyl)-n’,o-propylen-phosphorsaureester-diamid
  • n-(2-chloroethyl)-n’-(2-chloroethyl)-n’,o-propylenephosphoricaciddiamide
  • n-(2-chloroethyl)-n’-(2-chloroethyl)-n’,o-propylenephosphoricacidesterdiam
  • n,n-bis(beta-chloroethyl)-amino-n’,o-propylene-phosphoricacidesterdiamide
  • naxamide
  • nci-c01638
  • nsc-109724
  • z4942
  • ASTA Z-4942
  • ifosfamid
  • IFOSFAMIDE
  • NSC-1097
  • N,3-BIS(2-CHLOROETHYL)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORIN-2-AMINE 2-OXIDE
  • 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
  • 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-
  • 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
  • Iphosphamid
  • N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
  • Ifosfamide (FDA) USP24
  • IFOSFAMIDE USP STANDARD
  • 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,3,2-oxazaphosphorineoxide
  • A-4942
  • N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorinh-2-amine 2-Oxide, A-4942, Asta Z-4942, NSC-1097,
  • sophosphamide
  • 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide
  • Ifex, N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide
  • N,3-BIS(2-CHLOROETHYL)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINH-2-AMINE 2-OXIDE
  • 3-(2-chloroethyl)-2-((2-chloroethyl)aMino)-1,3,2-oxazaphosphinane 2-oxide
  • IfosfaMide USP
  • IfosfaMide 0.1
  • Ifosfamide, >=99%
  • 2,3-(n,n(sup1)-bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
  • 2-oxazaphosphorine,3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-3
  • 3-(2-chloroethyl)-2-((2-chloroethyl)amino)perhydro-2h-1,3,2-oxazaphosphorine
  • 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphori
  • 3,2-oxazaphosphorin-2-amine,n,3-bis(2-chloroethyl)tetrahydro-2h-2-oxide
  • 3,2-oxazaphosphorine,3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2-oxide
  • cyfos
  • N,3-bis(2-chloroethyl)-2-oxo-1-oxa-3-aza-2$l^{5}-phosphacyclohexan-2-amine
  • IfosfamideUsp27
  • 2-chloroethyl-[2-(2-chloroethyl)-1-keto-6-oxa-2-aza-1$l^{5}-phosphacyclohex-1-yl]amine
  • N,2-bis(2-chloroethyl)-1-oxo-6-oxa-2-aza-1$l^{5}-phosphacyclohexan-1-amine
  • 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydrochloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
  • Ifosfamide (500 mg)
  • (2R)-3-(2-chloroethyl)-2-[(2-chloroethyl)aMino]-1,3,2$l^{5}-oxazaphosphinan-2-one
  • IfoMide
  • IfosfaMide API
  • IfosfaMide(IsophosphaMide)
  • IfosphaMide
  • Isophosphamide / Ifosfamid
  • Ifosfamide,Isophosphamide,Isoe-ndoxan.
  • Ifosfamide CRS
Copyright 2019 ? ChemicalBook. All rights reserved